These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21666596)
1. [Idebenone (noben) -- from theory to practice]. Rachin AP; Averchenkova AA Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5):81-4. PubMed ID: 21666596 [No Abstract] [Full Text] [Related]
3. Introduction. Idebenone in the treatment of Friedreich ataxia. Pandolfo M J Neurol; 2009 Mar; 256 Suppl 1():1-2. PubMed ID: 19283343 [No Abstract] [Full Text] [Related]
4. [The use of noben (idebenone) in the complex treatment of episodic and chronic migraine]. Koreshkina MI Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(6):98-101. PubMed ID: 20726168 [No Abstract] [Full Text] [Related]
6. [The use of idebenone (noben) in neurological practice]. Damulin IV Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(11):66-71. PubMed ID: 17176607 [No Abstract] [Full Text] [Related]
8. Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases. Goldschmidt R; Arce PM; Khdour OM; Collin VC; Dey S; Jaruvangsanti J; Fash DM; Hecht SM Bioorg Med Chem; 2013 Feb; 21(4):969-78. PubMed ID: 23313093 [TBL] [Abstract][Full Text] [Related]
9. Co-enzyme Q10 and idebenone use in Friedreich's ataxia. Parkinson MH; Schulz JB; Giunti P J Neurochem; 2013 Aug; 126 Suppl 1():125-41. PubMed ID: 23859348 [TBL] [Abstract][Full Text] [Related]
10. An overview of the pathophysiology of neurodegenerative disorders. Willner C Altern Ther Health Med; 2004; 10(4):26-34; quiz 35, 96. PubMed ID: 15285272 [No Abstract] [Full Text] [Related]
11. How can we target oxidative stress in the treatment of neurodegenerative diseases? Akasaka H; Ruan KH Future Med Chem; 2016 May; 8(8):835-9. PubMed ID: 27173453 [No Abstract] [Full Text] [Related]
15. Applications of Antioxidants in Metabolic Disorders and Degenerative Diseases: Mechanistic Approach. Abdel-Daim MM; El-Tawil OS; Bungau SG; Atanasov AG Oxid Med Cell Longev; 2019; 2019():4179676. PubMed ID: 31467632 [No Abstract] [Full Text] [Related]
16. The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases. Danta CC; Piplani P Expert Opin Drug Discov; 2014 Oct; 9(10):1205-22. PubMed ID: 25056182 [TBL] [Abstract][Full Text] [Related]
17. [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. Voronkova KV; Meleshkov MN Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):27-32. PubMed ID: 18454094 [TBL] [Abstract][Full Text] [Related]